Myogenetic Oligodeoxynucleotide Restores Differentiation and Reverses Inflammation of Myoblasts Aggravated by Cancer-Conditioned Medium
Abstract
:1. Introduction
2. Results
2.1. iSN04 Recovers Differentiation of Human Myoblasts Aggravated by LoVo-CM
2.2. iSN04 Reverses Gene Expression in the Human Myoblasts Exposed to LoVo-CM
2.3. iSN04 Reverses Inflammation and Differentiation of TNF-α-Treated Human Myoblasts
3. Discussion
4. Materials and Methods
4.1. Chemicals
4.2. CM Preparation
4.3. Human Myoblast Culture
4.4. Immunocytochemistry
4.5. qPCR
4.6. Statistical Analysis
5. Conclusions
6. Patents
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Argiles, J.M.; Busquets, S.; Stemmler, B.; Lopez-Soriano, F.J. Cancer cachexia: Understanding the molecular basis. Nat. Rev. Cancer 2014, 14, 754–762. [Google Scholar] [CrossRef] [PubMed]
- Muscaritoli, M.; Bossola, M.; Aversa, Z.; Bellantone, R.; Faneli, F.R. Prevention and treatment of cancer cachexia: New insights into an old problem. Eur. J. Cancer 2006, 42, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Rowland, L.A.; Bal, N.C.; Periasamy, M. The role of skeletal-muscle-based thermogenic mechanisms in vertebrate endothermy. Biol. Rev. Camb. Philos. Soc. 2015, 90, 1279–1297. [Google Scholar] [CrossRef] [PubMed]
- Jensen, J.; Rustad, P.I.; Kolnes, A.J.; Lai, Y.C. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front. Physiol. 2011, 2, 112. [Google Scholar] [CrossRef] [PubMed]
- Periasamy, M.; Herrera, J.L.; Reis, F.C.G. Skeletal muscle thermogenesis and its role in whole body energy metabolism. Diabetes Metab. J. 2017, 41, 327–336. [Google Scholar] [CrossRef] [PubMed]
- Blauwhoff-Buskermolen, S.; Versteeg, K.S.; de van der Schueren, M.A.; den Braver, N.R.; Berkhof, J.; Langius, J.A.; Verheul, H.M. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J. Clin. Oncol. 2016, 34, 1339–1344. [Google Scholar] [CrossRef] [PubMed]
- Webster, J.M.; Kempen, L.J.A.P.; Hardy, R.S.; Langen, R.C.J. Inflammation and skeletal muscle wasting during cachexia. Front. Physiol. 2020, 11, 597675. [Google Scholar] [CrossRef]
- Dumont, N.A.; Bentzinger, C.F.; Sincennes, M.C.; Rudnicki, M.A. Satellite cells and skeletal muscle regeneration. Compr. Physiol. 2015, 5, 1027–1059. [Google Scholar]
- Millay, D.P.; O’Rourke, J.R.; Sutherland, L.B.; Bezprozvannaya, S.; Shelton, J.M.; Bassel-Duby, R.; Olson, E.N. Myomaker is a membrane activator of myoblast fusion and muscle formation. Nature 2013, 499, 301–305. [Google Scholar] [CrossRef]
- Bi, P.; Ramirez-Matinez, A.; Li, H.; Cannavino, J.; McAnally, J.R.; Shelton, J.M.; Sanchez-Otiz, E.; Bassel-Duby, R.; Olson, E.N. Control of muscle formation by the fusogenic micropeptide myomixer. Science 2017, 356, 323–327. [Google Scholar] [CrossRef]
- Lokireddy, S.; Wijesoma, I.W.; Bonala, S.; Wei, M.; Sze, S.K.; McFarlane, C.; Kambadur, R.; Sharma, M. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem. J. 2012, 446, 23–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marchildon, F.; Lamarche, E.; Lala-Tabbert, N.; St-Louis, C.; Wiper-Bergeron, N. Expression of CCAAT/enhancer binding protein beta in muscle satellite cells inhibits myogenesis in cancer cachexia. PLoS ONE 2015, 10, e0145583. [Google Scholar] [CrossRef] [PubMed]
- Zhang, G.; Liu, Z.; Ding, H.; Zhou, Y.; Doan, H.A.; Sin, K.W.T.; Zhu, Z.J.; Flores, R.; Wen, Y.; Gong, X.; et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 2017, 8, 589. [Google Scholar] [CrossRef] [PubMed]
- Miao, C.; Zhang, W.; Feng, L.; Gu, X.; Shen, Q.; Lu, S.; Fan, M.; Li, Y.; Guo, X.; Ma, Y.; et al. Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids 2021, 24, 923–938. [Google Scholar] [CrossRef] [PubMed]
- Shinji, S.; Umezawa, K.; Nihashi, Y.; Nakamura, S.; Shimosato, T.; Takaya, T. Identification of the myogenetic oligodeoxynucleotides (myoDNs) that promote differentiation of skeletal muscle myoblasts by targeting nucleolin. Front. Cell Dev. Biol. 2021, 8, 606706. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, S.; Yonekura, S.; Shimosato, T.; Takaya, T. Myogenetic oligodeoxynucleotide (myoDN) recovers the differentiation of skeletal muscle myoblasts deteriorated by diabetes mellitus. Front. Physiol. 2021, 12, 679152. [Google Scholar] [CrossRef] [PubMed]
- Nihashi, Y.; Shinji, S.; Umezawa, K.; Shimosato, T.; Ono, T.; Kagami, H.; Takaya, T. Myogenetic oligodeoxynucleotide complexed with berberine promotes differentiation of chicken myoblasts. Anim. Sci. J. 2021, 92, e13597. [Google Scholar] [CrossRef]
- Nohira, N.; Shinji, S.; Nakamura, S.; Nihashi, Y.; Shimosato, T.; Takaya, T. Myogenetic oligodeoxynucleotides as anti-nucleolin aptamers inhibit the growth of embryonal rhabdomyosarcoma cells. bioRxiv 2021, 464889. [Google Scholar]
- Berg, K.C.G.; Eide, P.W.; Eilertsen, I.A.; Johannessen, B.; Bruun, J.; Danielsen, S.A.; Bjornslett, M.; Meza-Zepeda, L.A.; Eknaes, M.; Lind, G.E.; et al. Multi-omics of 34 colorectal cancer cell lines—A resource for biomedical studies. Mol. Cancer 2017, 16, 116. [Google Scholar] [CrossRef]
- Langen, R.C.; Schols, A.M.; Kelders, M.C.; Wouters, E.F.; Janssen-Heininger, Y.M. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J. 2001, 15, 1169–1180. [Google Scholar] [CrossRef]
- Langley, B.; Thomas, M.; Bishop, A.; Sharma, M.; Gilmour, S.; Kambadur, R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 2002, 277, 49831–49840. [Google Scholar] [CrossRef] [PubMed]
- Broussard, S.R.; McCusker, R.H.; Novakofski, J.E.; Strle, K.; Shen, W.H.; Johnson, R.W.; Dantzer, R.; Kelley, K.W. IL-1β impairs insulin-like growth factor I-induced differentiation and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. J. Immunol. 2004, 172, 7713–7720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Desai, S.; Kumar, A.; Laskar, S.; Pandey, B.N. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 2013, 61, 54–62. [Google Scholar] [CrossRef]
- Ladner, K.J.; Caligiuri, M.A.; Guttridge, D.C. Tumor necrosis factor-regulated biphasic activation of NF-κB is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem. 2003, 278, 2294–2303. [Google Scholar] [CrossRef] [PubMed]
- Bivona Ill, J.J.; Mank, M.M.; Stapleton, R.D.; Files, D.C.; Toth, M.J.; Poynter, M.E. Skeletal muscle myofibers directly contribute to LPS-induced systemic inflammatory tone. Front. Pharmacol. 2022, 13, 917917. [Google Scholar] [CrossRef] [PubMed]
- Qiu, J.; Thapaliya, S.; Runkana, A.; Yang, Y.; Tsien, C.; Mohan, M.L.; Narayanan, A.; Eghtesad, B.; Mozdziak, P.E.; McDonald, C.; et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc. Natl. Acad. Sci. USA 2013, 110, 18162–18167. [Google Scholar] [CrossRef] [PubMed]
- Fang, L.; Wang, K.K.; Huang, Q.; Cheng, F.; Huang, F.; Liu, W.W. Nucleolin mediates LPS-induced expression of inflammatory mediators and activation of signaling pathways. Curr. Med. Sci. 2020, 40, 646–653. [Google Scholar] [CrossRef]
- Girvan, A.C.; Teng, Y.; Casson, L.K.; Thomas, S.D.; Juliger, S.; Ball, M.W.; Klein, J.B.; Pierce, W.M., Jr.; Barve, S.S.; Bates, P.J. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther. 2006, 5, 1790–1799. [Google Scholar] [CrossRef]
- Guttridge, D.C.; Mayo, M.W.; Madrid, L.V.; Wang, C.Y.; Baldwin, A.S., Jr. NF-κB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 2000, 289, 2363–2366. [Google Scholar] [CrossRef]
- Takagi, M.; Absalon, M.J.; McLure, K.G.; Kastan, M.B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005, 123, 49–63. [Google Scholar] [CrossRef]
- Chen, J.; Guo, K.; Kastan, M.B. Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA. J. Biol. Chem. 2012, 287, 16467–16476. [Google Scholar] [CrossRef] [PubMed]
- Cerone, M.A.; Marchetti, A.; Bossi, G.; Blandino, G.; Sacchi, A.; Soddu, S. p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death Differ. 2000, 7, 506–508. [Google Scholar] [CrossRef] [Green Version]
- Porrello, A.; Cerone, M.A.; Coen, S.; Gurtner, A.; Fontemaggi, G.; Cimino, L.; Piaggio, G.; Sacchi, A.; Soddu, S. p53 regulates myogenesis by triggering the differentiation activity of pRb. J. Cell Biol. 2000, 151, 1295–1304. [Google Scholar] [CrossRef]
- Pal, S.; Bhattacharjee, A.; Ali, A.; Mandal, N.C.; Mandal, S.C.; Pal, M. Chronic inflammation and cancer: Potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J. Inflamm. 2014, 11, 23. [Google Scholar] [CrossRef]
- VanderVeen, B.N.; Murphy, E.A.; Carson, J.A. The impact of immune cells on the skeletal muscle microenvironment during cancer cachexia. Front. Physiol. 2020, 11, 1037. [Google Scholar] [CrossRef] [PubMed]
- Nihashi, Y.; Miyoshi, M.; Umezawa, K.; Shimosato, T.; Takaya, T. Identification of a novel osteogenetic oligodeoxynucleotide (osteoDN) that promotes osteoblast differentiation in a TLR9-independent manner. Nanomaterials 2022, 12, 1680. [Google Scholar] [CrossRef] [PubMed]
- Nihashi, Y.; Umezawa, K.; Shinji, S.; Hamaguchi, Y.; Kobayashi, H.; Kono, T.; Ono, T.; Kagami, H.; Takaya, T. Distinct cell proliferation, myogenic differentiation, and gene expression in skeletal muscle myoblasts of layer and broiler chickens. Sci. Rep. 2019, 9, 16527. [Google Scholar] [CrossRef] [Green Version]
- Nihashi, Y.; Yamamoto, M.; Shimosato, T.; Takaya, T. Myogenetic oligodeoxynucleotide restores differentiation and reverses inflammation of myoblasts aggravated by cancer-conditioned medium. bioRxiv 2021, 469038. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nihashi, Y.; Yamamoto, M.; Shimosato, T.; Takaya, T. Myogenetic Oligodeoxynucleotide Restores Differentiation and Reverses Inflammation of Myoblasts Aggravated by Cancer-Conditioned Medium. Muscles 2022, 1, 111-120. https://doi.org/10.3390/muscles1020012
Nihashi Y, Yamamoto M, Shimosato T, Takaya T. Myogenetic Oligodeoxynucleotide Restores Differentiation and Reverses Inflammation of Myoblasts Aggravated by Cancer-Conditioned Medium. Muscles. 2022; 1(2):111-120. https://doi.org/10.3390/muscles1020012
Chicago/Turabian StyleNihashi, Yuma, Machi Yamamoto, Takeshi Shimosato, and Tomohide Takaya. 2022. "Myogenetic Oligodeoxynucleotide Restores Differentiation and Reverses Inflammation of Myoblasts Aggravated by Cancer-Conditioned Medium" Muscles 1, no. 2: 111-120. https://doi.org/10.3390/muscles1020012